Abstract
Ischemic stroke is one of the leading causes of death and disability worldwide. There is no effective treatment for ischemic stroke apart from thrombolytic therapy, which has a narrow therapeutic time window. Gene therapy has proven to be effective in experimental stroke, but it suffers from disadvantages that limit its clinical application, such as difficulty in intracranial delivering of therapeutic genes, low efficacy in transfecting host cells and long-term expression of exogenous genes. Delivering therapeutic genes to the ischemic brain via stem cells is an alternative strategy of combined gene and stem cell therapy. There are advantages for stem cell-mediated gene delivery as opposed to direct gene transfer. In recent years, studies used stem cells that over-express different neurotrophic factors, such as BDNF, GDNT, or NT3, and found that the delivery of these genetically-modified stem cells to animal models of ischemic stroke is safe and effective, thus suggesting that stem cell-based gene therapy may be a promising treatment for stroke. This review summarizes the advantages and recent progress of stem cell-based gene therapy for ischemic stroke. We also discuss the relevant strategy for optimizing stem cell-based gene therapy and discuss the potential strategies for its future application.
Keywords: Embryonic stem cell, gene therapy, stem cell, ischemic stroke, mesenchymal stem cell, neural stem cell
Current Drug Targets
Title:Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Volume: 14 Issue: 1
Author(s): Chao Chen, Yongting Wang and Guo-Yuan Yang
Affiliation:
Keywords: Embryonic stem cell, gene therapy, stem cell, ischemic stroke, mesenchymal stem cell, neural stem cell
Abstract: Ischemic stroke is one of the leading causes of death and disability worldwide. There is no effective treatment for ischemic stroke apart from thrombolytic therapy, which has a narrow therapeutic time window. Gene therapy has proven to be effective in experimental stroke, but it suffers from disadvantages that limit its clinical application, such as difficulty in intracranial delivering of therapeutic genes, low efficacy in transfecting host cells and long-term expression of exogenous genes. Delivering therapeutic genes to the ischemic brain via stem cells is an alternative strategy of combined gene and stem cell therapy. There are advantages for stem cell-mediated gene delivery as opposed to direct gene transfer. In recent years, studies used stem cells that over-express different neurotrophic factors, such as BDNF, GDNT, or NT3, and found that the delivery of these genetically-modified stem cells to animal models of ischemic stroke is safe and effective, thus suggesting that stem cell-based gene therapy may be a promising treatment for stroke. This review summarizes the advantages and recent progress of stem cell-based gene therapy for ischemic stroke. We also discuss the relevant strategy for optimizing stem cell-based gene therapy and discuss the potential strategies for its future application.
Export Options
About this article
Cite this article as:
Chen Chao, Wang Yongting and Yang Guo-Yuan, Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives, Current Drug Targets 2013; 14 (1) . https://dx.doi.org/10.2174/1389450111314010009
DOI https://dx.doi.org/10.2174/1389450111314010009 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impact of IL-17 in Atherosclerosis
Current Medicinal Chemistry From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Confocal Laser Scanning Microscope, Raman Microscopy and Western Blotting to Evaluate Inflammatory Response after Myocardial Infarction
Current Vascular Pharmacology Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets Medicinal Plants against Ischemic Stroke
Current Pharmaceutical Biotechnology Sirolimus and its Analogs and its Effects on Vascular Diseases
Current Pharmaceutical Design Diagnostic Value of HLA Typing in Pathogenesis of Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Nutritional Aspects Relating to the Developmental Origins of Health and Disease
Current Women`s Health Reviews The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Cell Responses to Oxidative Stressors
Current Pharmaceutical Design Role of Mitochondria on Muscle Cell Death and Meat Tenderization
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Editorial [Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options]
Current Respiratory Medicine Reviews Pharmacological Management of No Reflow During Percutaneous Coronary Intervention
Current Vascular Pharmacology Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design The Role of Cytokines in Pharmacological Modulation of Hepatic Ischemia/Reperfusion Injury
Current Pharmaceutical Design